Tone mix
Week by week 52 weeks
Share of Halozyme Therapeutics, Inc.'s 167 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jul 20, 2026 · tone +100Halozyme Therapeutics (NASDAQ:HALO) Given "Buy" Rating at HC Wainwright+82
- Week of Jun 1, 2026 · tone +100FinancialContent - Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today+68
- Week of Sep 22, 2025 · tone +99Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, HC Wainwright Analyst Says+64
- Week of Oct 12, 2026 · tone +100Halozyme Therapeutics (NASDAQ:HALO) Stock Price Up 5.9% After Analyst Upgrade+58
- Week of Oct 6, 2025 · tone +100Strong And Rising: Halozyme Therapeutics Stock May Have More Upside+57
- Week of Oct 13, 2025 · tone 0Mirae Asset Global Investments Co. Ltd. Raises Position in Halozyme Therapeutics, Inc. $HALO-45
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Halozyme Therapeutics, Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | +50 |
| Last 30 sessions | 15 | +51 |
| Last 90 sessions | 38 | +40 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Tuesday, October 27, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.insidermonkey.com · 1 outletStrong Royalties and New Launches Accelerate Halozyme Therapeutics' (HALO) Growth MomentumPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Strong Royalties and New Launches Accelerate Halozyme Therapeutics' (HALO) Growth Momentum | www.insidermonkey.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletAllarity Therapeutics (NASDAQ:ALLR) vs. Halozyme Therapeutics (NASDAQ:HALO) Critical AnalysisNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Allarity Therapeutics (NASDAQ:ALLR) vs. Halozyme Therapeutics (NASDAQ:HALO) Critical Analysis | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletHalozyme Therapeutics (NASDAQ:HALO) Stock Price Up 5.9% After Analyst UpgradePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Halozyme Therapeutics (NASDAQ:HALO) Stock Price Up 5.9% After Analyst Upgrade | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.tickerreport.com · 1 outletHalozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $130.00Positive
- www.dailypolitical.com · 1 outletHalozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, TD Cowen Analyst SaysPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $130.00 | www.tickerreport.com | 1 | Positive |
| Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, TD Cowen Analyst Says | www.dailypolitical.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 9, 2026
3 headlines, average tone +66: 2 positive, 1 neutral and 0 negative. Showing all 3.
- www.dailypolitical.com · 1 outletHalozyme Therapeutics (NASDAQ:HALO) Stock Gets Price Target Bump from JPMorgan Chase & Co.Positive
- www.tickerreport.com · 1 outletHalozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysPositive
- www.themarketsdaily.com · 1 outletHalozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in StockNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Halozyme Therapeutics (NASDAQ:HALO) Stock Gets Price Target Bump from JPMorgan Chase & Co. | www.dailypolitical.com | 1 | Positive |
| Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says | www.tickerreport.com | 1 | Positive |
| Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in Stock | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Halozyme Therapeutics, Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.